312 related articles for article (PubMed ID: 36875718)
21. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
22. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
23. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
24. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
25. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
26. B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
Dogan A; Siegel D; Tran N; Fu A; Fowler J; Belani R; Landgren O
Blood Cancer J; 2020 Jun; 10(6):73. PubMed ID: 32606424
[TBL] [Abstract][Full Text] [Related]
27. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
28. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
de Weerdt I; Lameris R; Ruben JM; de Boer R; Kloosterman J; King LA; Levin MD; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
Clin Cancer Res; 2021 Mar; 27(6):1744-1755. PubMed ID: 33451981
[TBL] [Abstract][Full Text] [Related]
29. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
30. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
32. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
33. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
34. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
35. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
36. Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
Hua G; Scanlan R; Straining R; Carlson DS
J Adv Pract Oncol; 2023 Mar; 14(2):163-171. PubMed ID: 37009408
[TBL] [Abstract][Full Text] [Related]
37. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
[TBL] [Abstract][Full Text] [Related]
38. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
39. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau OS; Nielsen K; Davis C; Patel JH; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg JD; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona R
Blood; 2024 Apr; ():. PubMed ID: 38657201
[TBL] [Abstract][Full Text] [Related]
40. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
García-Guerrero E; Rodríguez-Lobato LG; Sierro-Martínez B; Danhof S; Bates S; Frenz S; Haertle L; Götz R; Sauer M; Rasche L; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Prommersberger SR
Haematologica; 2023 Feb; 108(2):568-580. PubMed ID: 36722406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
